Precigen (NASDAQ:PGEN) COO Rutul Shah Sells 34,658 Shares

Precigen, Inc. (NASDAQ:PGEN) COO Rutul Shah sold 34,658 shares of the company’s stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $7.50, for a total transaction of $259,935.00. Following the transaction, the chief operating officer directly owned 465,012 shares in the company, valued at $3,487,590. The trade was a 6.94% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Precigen Stock Performance

Shares of NASDAQ:PGEN opened at $7.28 on Wednesday. Precigen, Inc. has a 12 month low of $2.99 and a 12 month high of $7.55. The business has a 50-day moving average of $5.91 and a two-hundred day moving average of $4.69. The company has a debt-to-equity ratio of 2.15, a current ratio of 4.58 and a quick ratio of 3.89. The firm has a market capitalization of $2.60 billion, a PE ratio of -7.00 and a beta of 1.02.

Precigen (NASDAQ:PGEN) last issued its earnings results on Tuesday, August 4th. The biotechnology company reported $0.05 earnings per share for the quarter, topping the consensus estimate of ($0.01) by $0.06. Precigen had a positive return on equity of 423.75% and a negative net margin of 183.98%.The company had revenue of $54.98 million during the quarter, compared to the consensus estimate of $27.98 million. The company’s revenue was up 6322.7% compared to the same quarter last year. As a group, research analysts forecast that Precigen, Inc. will post 0.25 earnings per share for the current year.

Key Headlines Impacting Precigen

Here are the key news stories impacting Precigen this week:

• Positive Sentiment: Strong PAPZIMEOS sales and quarterly profitability: Precigen reported that PAPZIMEOS generated $53.1 million in second-quarter net product revenue, more than double the previous quarter. The company said the performance marked a commercial inflection point and helped it achieve quarterly profitability, supporting the stock’s upward momentum. Precigen’s Strong Second Quarter Signals Significant Growth, Validates AdenoVerse Platform
• Positive Sentiment: Pipeline progress adds to the investment case: PRGN-2009 is advancing in HPV-driven cancers, while management highlighted the broader potential of its AdenoVerse therapeutic platform. The combination of commercial revenue and pipeline development is reinforcing expectations for further growth. Precigen’s Strong Second Quarter Signals Significant Growth, Validates AdenoVerse Platform
• Positive Sentiment: New 1-year high: PGEN reached a new 52-week high, signaling strong recent trading momentum as investors responded to the company’s improved operating performance. Precigen Reaches New 1-Year High
• Positive Sentiment: Director purchase: Director Nancy H. Agee bought 3,411 shares at an average price of $7.23, modestly increasing her ownership. The purchase may be viewed as a sign of confidence in Precigen’s outlook.
• Neutral Sentiment: COO share sales were tax-related: COO Rutul R. Shah sold a combined 50,000 shares at approximately $7.50 under a pre-arranged Rule 10b5-1 plan to cover tax withholding tied to vested equity awards. Because the sales were planned and administrative, they provide limited bearish information, although they reduce his holdings.
• Neutral Sentiment: Short-interest data is inconclusive: Reported short interest was zero, making the published change and short-interest ratio unreliable as indicators of investor positioning.

Institutional Trading of Precigen

A number of institutional investors and hedge funds have recently modified their holdings of the company. Xponance LLC raised its position in shares of Precigen by 21.3% during the 4th quarter. Xponance LLC now owns 14,191 shares of the biotechnology company’s stock valued at $59,000 after buying an additional 2,496 shares in the last quarter. BNP Paribas Financial Markets increased its stake in Precigen by 6.1% during the third quarter. BNP Paribas Financial Markets now owns 51,796 shares of the biotechnology company’s stock worth $170,000 after acquiring an additional 2,993 shares during the last quarter. Composition Wealth LLC increased its position in shares of Precigen by 16.5% during the 4th quarter. Composition Wealth LLC now owns 21,217 shares of the biotechnology company’s stock valued at $89,000 after purchasing an additional 3,000 shares during the last quarter. Intech Investment Management LLC grew its stake in shares of Precigen by 5.2% during the fourth quarter. Intech Investment Management LLC now owns 63,018 shares of the biotechnology company’s stock valued at $263,000 after buying an additional 3,137 shares during the last quarter. Finally, Cetera Investment Advisers raised its holdings in shares of Precigen by 0.9% in the first quarter. Cetera Investment Advisers now owns 374,514 shares of the biotechnology company’s stock worth $1,449,000 after buying an additional 3,250 shares during the period. 33.51% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts recently commented on the company. Wall Street Zen upgraded Precigen from a “hold” rating to a “strong-buy” rating in a research report on Saturday, August 8th. HC Wainwright raised their target price on shares of Precigen from $14.00 to $18.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. Zacks Research upgraded Precigen from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, August 5th. Citigroup reiterated an “outperform” rating on shares of Precigen in a research report on Thursday, May 14th. Finally, Citizens Jmp upped their target price on Precigen from $9.00 to $11.00 and gave the company a “market outperform” rating in a report on Thursday, May 14th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $14.50.

About Precigen

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.